# A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)

> **NCT00300885** · PHASE3 · TERMINATED · sponsor: **Bayer** · enrollment: 926 (actual)

## Conditions studied

- Carcinoma, Non-Small Cell Lung

## Interventions

- **DRUG:** Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel
- **DRUG:** Carboplatin plus Paclitaxel

## Key facts

- **NCT ID:** NCT00300885
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-02
- **Primary completion:** 2007-10
- **Final completion:** 2009-02
- **Target enrollment:** 926 (ACTUAL)
- **Why stopped:** Based on the results of the interim analysis, it was determined that the study would not meet its primary efficacy endpoint and the study was terminated early.
- **Last updated:** 2014-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00300885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00300885, "A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-08-12 from https://api.ai-analytics.org/clinical/NCT00300885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*